Emergent BioSolutions (EBS)
6.21
-0.02 (0.32%)
Upcoming Events
Latest Headlines
Emergent BioSolutions buys back $75M in senior unsecured notes
September 3, 2026 7:45 AM - StreetInsider
Emergent BioSolutions Completes Repurchase of $75 Million Aggregate Principal Amount of Senior Unsecured Notes
September 3, 2026 7:45 AM - StreetInsider
Form 8-K Emergent BioSolutions For: Aug 18
September 1, 2026 4:13 PM - SEC Filing
Emergent BioSolutions gets $24M BARDA contract for anthrax vaccine
September 1, 2026 7:55 AM - StreetInsider
Emergent BioSolutions Awarded Contract Modification Valued at Approximately $24 Million for CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted)
September 1, 2026 7:55 AM - StreetInsider
Emergent BioSolutions wins Canada NARCAN supply deal through 2029
August 31, 2026 7:55 AM - StreetInsider
Emergent BioSolutions Awarded Government of Canada Standing Offer for NARCAN® Nasal Spray
August 31, 2026 7:55 AM - StreetInsider
Emergent BioSolutions Reinforces Commitment to Opioid Overdose Education and Preparedness on International Overdose Awareness Day
August 31, 2026 7:54 AM - StreetInsider
JPMorgan Reinstates Emergent BioSolutions (EBS) at Underweight
August 21, 2026 3:28 AM - StreetInsider
Form SCHEDULE 13G Emergent BioSolutions Filed by: AMERICAN CENTURY INVESTMENT MANAGEMENT INC
August 14, 2026 2:37 PM - SEC Filing
Form 3 Emergent BioSolutions For: Aug 05 Filed by: Duatschek Stephanie
August 12, 2026 9:17 AM - SEC Filing
Emergent BioSolutions (EBS) PT Lowered to $10 at H.C. Wainwright
August 10, 2026 6:49 AM - StreetInsider
Form 10-Q Emergent BioSolutions For: Jun 30
August 6, 2026 6:02 AM - SEC Filing
Emergent BioSolutions (EBS) Tops Q2 EPS by 49c
August 6, 2026 2:17 AM - StreetInsider
Emergent BioSolutions highlights biological threat risks amid AI advances
August 5, 2026 4:08 PM - StreetInsider
Form 8-K Emergent BioSolutions For: Aug 05
August 5, 2026 4:07 PM - SEC Filing
Emergent BioSolutions Commits to Cross-Sector Collaboration Against Biological Threats in an Evolving Global Security Environment
August 5, 2026 4:07 PM - Globe NewsWire
Emergent BioSolutions Reports Second Quarter 2026 Financial Results
August 5, 2026 4:07 PM - StreetInsider
Form SCHEDULE 13G/A Emergent BioSolutions Filed by: VANGUARD CAPITAL MANAGEMENT LLC
July 31, 2026 10:21 AM - SEC Filing
Form SCHEDULE 13G/A Emergent BioSolutions Filed by: BlackRock, Inc.
July 28, 2026 4:45 PM - SEC Filing
Emergent BioSolutions to Report Second Quarter 2026 Financial Results on August 5, 2026
July 22, 2026 4:01 PM - StreetInsider
Form EFFECT Erste Group Bank AG/ADR
July 9, 2026 6:04 AM - SEC Filing
Form 4 Emergent BioSolutions For: Jul 01 Filed by: Williams Paul Anthony
July 2, 2026 12:57 PM - SEC Filing
Form F-6 Erste Group Bank AG/ADR Filed by: JPMorgan Chase Bank, N.A. - ADR Depositary
July 1, 2026 5:26 PM - SEC Filing
Form 144 Emergent BioSolutions Filed by: Williams Paul Anthony
July 1, 2026 4:13 PM - SEC Filing
Form 8-K Emergent BioSolutions For: Jun 26
June 29, 2026 11:15 AM - SEC Filing
Emergent BioSolutions wins $52.7M U.S. government smallpox vaccine deal
June 29, 2026 9:13 AM - StreetInsider
Emergent BioSolutions Secures Contract Modification Valued at Approximately $52.7 Million for ACAM2000® (Smallpox and Mpox (Vaccinia) Vaccine, Live) from the U.S. Government
June 29, 2026 9:13 AM - Globe NewsWire
Form 4 Emergent BioSolutions For: Jun 08 Filed by: Williams Paul Anthony
June 10, 2026 3:09 PM - SEC Filing
Form 4 Emergent BioSolutions For: Jun 08 Filed by: LINDAHL RICHARD S
June 10, 2026 3:08 PM - SEC Filing
Form 4 Emergent BioSolutions For: Jun 08 Filed by: Glessner Coleen
June 10, 2026 3:07 PM - SEC Filing
Form 4 Emergent BioSolutions For: Jun 08 Filed by: Hartzel William
June 10, 2026 3:06 PM - SEC Filing
Full Article List